Sutinat 12.5mg Capsule (Sunitinib)
Prescription RequiredManufactured By
Natco
Pack Of
28
Salt Composition
Sunitinib
Storage
Keep in cold place
Fast Delivery
Easy Returns
Secure Payments
Up to 60% Discounts
ALL SUBSTITUTES
Sutent 50mg Capsule
Sunicine 50mg Capsule
Sutib 12.5mg Capsule
Nitnib 12.5mg Capsule
Sutenamo 25mg Capsule
Sunitcap 25mg Capsule
Sunitcap 12.5mg Capsule
Sunisam 12.5mg Capsule
Sugistran 12.5mg Capsule
Tunib 25mg Capsule
Sutib 25mg Capsule
Svitinib 25mg Capsule
Adsunib 12.5mg Capsule
Healtinib 50mg Capsule
Tunib 12.5mg Capsule
Sutekast 12.5mg Capsule
Sunicine 12.5mg Capsule
Sunicine 25mg Capsule
Sutent 25mg Capsule
Sutent 12.5mg Capsule
Sutinat 50mg Capsule
Sutinat 25mg Capsule
Overview
Sutinat 12.5mg Capsules is a prescription-based anticancer medicine used in the treatment of kidney cancer and gastrointestinal stromal tumors. The active ingredient of the Sutinat is Sunitinib which belongs to the drug class of Tyrosine Kinase Inhibitors.
It works by binding and inhibition of certain protein (tyrosine kinase) on the surface of the cell, which leads to the development of cancer cells.
In addition, this process inhibits the development of new blood vessels inside the cancer cells. Sunitinib Capsules is usually given in combination with another anticancer medicine as a part of combination therapy to increase the efficacy of the treatment.
Quick Product Facts
| Field | Publication wording |
|---|---|
| Brand | sutinat |
| Generic / Active Ingredient | Sunitinib |
| Strength | 12.5 |
| Dosage Form | Capsule |
| Manufacturer / Marketer | Natco |
| Pack Size | 28 |
| Prescription Required | Yes |
| Therapeutic Categories | Cancer Medicines |
| Uses | Gastrointestinal Stromal Tumors |
Uses and Indications
Kidney Cancer, Gastrointestinal stromal tumors
Side Effects of Sutinat 12.5mg Capsule
The human body shows undesired symptoms after taking Sutinat 12.5mg Capsule (Sunitinib). Usually, they disappear with time as the body adjusts to the medicine. These side effects don't need special medical attention. It is advised to consult your doctor if these symptoms become unmanageable.
Common or Clinically Frequent Side Effects
- Some of the common side effects of Sutinat Capsule are mentioned below:
- ● Fatigue
- ● Cough
- ● insomnia
- ● Headache
- ● Dry or itchy skin
- ● Nausea & Vomiting
- ● Diarrhea and Constipation
- ● Hand-foot-and-mouth disease
- ● Increased bilirubin in the blood
- ● Hair loss or change in color of hair
Serious Side Effects
- ● Heart failure
- ● Liver failure
- ● Proteinuria
- ● Hemorrhage
- ● low thyroid function
- ● low blood sugar
- ● Acute kidney injury
- ● Pulmonary arterial hypertension
- ● Interstitial lung disease (inflammation of lung walls)
Sutinat 12.5mg Capsule Dosage and How To Take It
Sunitinib 12.5mg Capsule (Sutinat) is a prescription-based anticancer drug that should be administered orally. It is advised to take this capsule after consulting your healthcare expert.
This capsule should be swallowed as a whole with water. Don't crush, chew, or break it. It can be taken with or without food. Never skip a dose or double dose.
Safety Advice for Sutinat 12.5mg Capsule
- ● Alcohol: The interaction of alcohol with this drug is still unknown. It is advisable not to consume alcohol while taking Sutinat 12.5mg Capsule (Sunitinib). It is advised to consult your doctor for further information.
- ● Pregnancy: Sunitinib 12.5mg Capsule (Sutinat) may be considered unsafe during pregnancy. Please consult your doctor in such condition.
- ● Breastfeeding: Sutinat 12.5mg Capsule (Sunitinib) is probably not safe if you're breastfeeding. Kindly consult your doctor.
- ● Driving: It is advisable not to drive or operate heavy machinery as you may feel dizzy after taking Sunitinib 12.5mg Capsule (Sutinat).
- ● Kidney: Share your medical history with your healthcare expert in case of kidney disease before taking Sutinat 12.5mg Capsule (Sunitinib).
- ● Liver: Inform your doctor before starting Sunitinib 12.5mg Capsule (Sutinat) if you have liver disease to avoid any serious side effects.
FAQs About Sutinat 12.5mg Capsule
What is the best way to take a Sutinat 12.5mg Capsule (Sunitinib)?
Your doctor will decide the dosage for taking the drug. You must take it with or without food as per prescription. Do not chew, crush, or break the capsule, just take it whole with water.
Does Sunitinib 12.5mg Capsule (Sutinat) have effects on skin and hair?
Yes, taking Sunitinib can cause hair loss and a change in its colour. It can also result in dry and itchy skin. In severe conditions, this also results in hand-foot syndrome.
How does Sutinat shrink the tumor?
Sutinat blocks the enzymatic activity that helps in the multiplication of the tumor cell. In such a way, it shrinks the tumor cells and slows down the growth of cancer cells.
How does a Sutinat 12.5mg Capsule (Sunitinib) affect the blood?
Sutinat may cause anemia (low RBC count) and thrombocytopenia (low platelet count). These may elevate the chances of blood infection and bleeding.
Is it safe to give Sunitinib 12.5mg Capsule (Sutinat) to patients with the thyroid problem?
Yes, it is safe to give Sunitinib to patients with thyroid problems. The healthcare expert will check for thyroid levels regularly. This medicine can affect the thyroid and result in hypothyroidism (a low active thyroid gland) or hyperthyroidism (a highly active thyroid gland).
References
● Demlová, R., Turjap, M., Peš, O., Kostolanská, K., & Juřica, J. (2020). Therapeutic drug monitoring of sunitinib in gastrointestinal stromal tumors and metastatic renal cell carcinoma in adults—a review. Therapeutic Drug Monitoring, 42(1), 20-32.
● Mulet-Margalef, N., & Garcia-del-Muro, X. (2016). Sunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectives. OncoTargets and therapy, 7573-7582.
● Adams, V. R., & Leggas, M. (2007). Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. Clinical therapeutics, 29(7), 1338-1353.
● Gan, H. K., Seruga, B., & Knox, J. J. (2009). Sunitinib in solid tumors. Expert opinion on investigational drugs, 18(6), 821-834.
● Goodman, V. L., Rock, E. P., Dagher, R., Ramchandani, R. P., Abraham, S., Gobburu, J. V., ... & Pazdur, R. (2007). Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clinical Cancer Research, 13(5), 1367-1373.
● Le Tourneau, C., Raymond, E., & Faivre, S. (2007). Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST). Therapeutics and clinical risk management, 3(2), 341-348.
Marketer Details
Natco
Author Details
Written By:
Nonish Sharma
I am a medical content writer with a strong academic background in life sciences, holding an M.Sc. in Biotechnology... Read More
Reviewed By:
Vaibhav Shakya
Dr. Vaibhav Shakya, MD, is a Medical reviewer and medicine expert at Globans Pharma, with more than 9 years of experienc... Read More
Want to know More
Check our Editor Policy
Disclaimer
Globanspharma main goal is to ensure that its consumers get correct, authentic, and reliable information that has been examined by medical professionals. This website's content has only been created for informational purposes. However, this is not meant to replace the medical advice and treatment given by a qualified physician. The information presented herein may not cover everything about particular lab tests, medicines, and health conditions, all possible side effects, and warnings. Please discuss all your queries related to any medication and illness with your doctor. We intend to support and maintain the doctor-patient relationship, not to substitute it or take its place.
